# Zura Bio Limited Class A (ZURA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.23, market value $597 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Zura Bio Limited Class A reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.3%** (5-yr avg -14.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -67.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -76.7%**. Earnings per share fell 76.7%.

## Financial health
- **Current ratio: 9.05** (quick 9.05). Current assets cover the next year's liabilities 9.05 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Zura Bio Limited Class A does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 201.0%** (YTD 18.9%, 3-mo 83.2%). The shares are up 201.0% over twelve months including dividends.
- **From 52-week high: -16.3%** (231.4% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.73** (volatility 96%). Beta of 1.73 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ZURA · Page: https://foliofundamentals.com/stocks/zura

Not investment advice.